Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Stefan Willmann"'
Autor:
Tianxing Liu, Kensei Hashizume, Eva Krieg, Huijun Chen, Yuki Mukaida, Kirstin Thelen, Frauke Friedrichs, Stefan Willmann, Stephan Schwers, Alexander Solms, Rosie Yu
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 4, Pp n/a-n/a (2024)
Abstract The inhibition of coagulation factor XI (FXI) presents an attractive approach for anticoagulation as it is not expected to increase the risk of clinically relevant bleeding and is anticipated to be at least as effective as currently availabl
Externí odkaz:
https://doaj.org/article/cb479031dd4144f68d40844bb322cbcc
Autor:
Stefan Willmann, Ibrahim Ince, Maurice Ahsman, Katrin Coboeken, Yang Zhang, Kirstin Thelen, Dagmar Kubitza, Peter Zannikos, Wangda Zhou, Liza Miriam Pina, Teun Post, Jörg Lippert
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 8, Pp 1111-1121 (2022)
Abstract Rivaroxaban is approved in various regions for the treatment of acute venous thromboembolism (VTE) in children aged between 0 and 18 years and was recently investigated for thromboprophylaxis in children aged between 2 and 8 years (with body
Externí odkaz:
https://doaj.org/article/84f2ca20cce34d809d5416226dfd0fe3
Autor:
Stefan Willmann, Katrin Coboeken, Yang Zhang, Hannah Mayer, Ibrahim Ince, Emir Mesic, Kirstin Thelen, Dagmar Kubitza, Anthonie W. A. Lensing, Haitao Yang, Peijuan Zhu, Wolfgang Mück, Henk‐Jan Drenth, Jörg Lippert
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1195-1207 (2021)
Abstract Rivaroxaban has been investigated in the EINSTEIN‐Jr program for the treatment of acute venous thromboembolism (VTE) in children aged 0 to 18 years and in the UNIVERSE program for thromboprophylaxis in children aged 2 to 8 years with conge
Externí odkaz:
https://doaj.org/article/b607066a22fb4e818ec3a9900c55f325
Autor:
Stefan Willmann, Eleonora Marostica, Nelleke Snelder, Alexander Solms, Markus Jensen, Maximilian Lobmeyer, Anthonie W. A. Lensing, Claudette Bethune, Erin Morgan, Rosie Z. Yu, Yanfeng Wang, Shiangtung W. Jung, Richard Geary, Sanjay Bhanot
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 890-901 (2021)
Abstract IONIS‐FXIRX (BAY2306001) is an antisense oligonucleotide that inhibits the synthesis of coagulation factor XI (FXI) and has been investigated in healthy volunteers and patients with end‐stage renal disease (ESRD). FXI‐LICA (BAY2976217)
Externí odkaz:
https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9
Autor:
Humberto García Aguilar, Matthias Gorenflo, D. Dunbar Ivy, Shahin Moledina, Biagio Castaldi, Hidekazu Ishida, Paweł Cześniewicz, Jacek Kusa, Oliver Miera, Joseph Pattathu, Ken‐Pen Weng, Laszlo Ablonczy, Christian Apitz, Marta Katona, Kenichi Kurosaki, Tomas Pulido, Hiroyuki Yamagishi, Kazushi Yasuda, Galia Cisternas, Melanie Goth, Susanne Lippert, Anna Radomskyj, Soundos Saleh, Stefan Willmann, Gabriela Wirsching, Damien Bonnet, Maurice Beghetti
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 3, Pp n/a-n/a (2022)
Abstract Riociguat, a soluble guanylate cyclase stimulator, is approved for treatment of adults with pulmonary arterial hypertension (PAH). The safety, tolerability, and pharmacokinetics (PK) of oral riociguat in a pediatric population with PAH was a
Externí odkaz:
https://doaj.org/article/b9ede33b5c434f00ad5c57409c295608
Autor:
Alexander Solms, Matthias Frede, Scott D. Berkowitz, Anne Hermanowski‐Vosatka, Dagmar Kubitza, Wolfgang Mueck, Theodore E. Spiro, Stefan Willmann, Xiaoyu Yan, Liping Zhang, Dirk Garmann
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 11, Pp 805-814 (2019)
Prothrombin time (PT) is a measure of coagulation status and was assessed in the majority of patients in the rivaroxaban phase II and III clinical trials as a pharmacodynamic marker. In the absence of sufficient phase III pharmacokinetic (PK) data to
Externí odkaz:
https://doaj.org/article/3284b20cca0648198b411dd0ffa0f05c
Autor:
Sonja E. Zapke, Stefan Willmann, Scott-Oliver Grebe, Kristin Menke, Petra A. Thürmann, Sven Schmiedl
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
This study compared simulations of a physiologically based pharmacokinetic (PBPK) model implemented for cyclosporine with drug levels from therapeutic drug monitoring to evaluate the predictive performance of a PBPK model in a clinical population. Ba
Externí odkaz:
https://doaj.org/article/222a3b0c4c544faf947e677877a37850
Autor:
Stefan Willmann, Matthias Frei, Gabriele Sutter, Katrin Coboeken, Thomas Wendl, Thomas Eissing, Jörg Lippert, Heino Stass
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 9, Pp 654-663 (2019)
Moxifloxacin is a widely used fluoroquinolone for the treatment of complicated intra‐abdominal infections. We applied physiologically‐based pharmacokinetic (PBPK) and population pharmacokinetic (popPK) modeling to support dose selection in pediat
Externí odkaz:
https://doaj.org/article/6dd0037f4773496589f886f7a3e3dd5b
Autor:
Dagmar Kubitza, Stefan Willmann, Michael Becka, Kirstin Thelen, Guy Young, Leonardo R. Brandão, Paul Monagle, Christoph Male, Anthony Chan, Gili Kennet, Ida Martinelli, Paola Saracco, Anthonie W. A. Lensing
Publikováno v:
Thrombosis Journal, Vol 16, Iss 1, Pp 1-13 (2018)
Abstract Background The EINSTEIN-Jr program will evaluate rivaroxaban for the treatment of venous thromboembolism (VTE) in children, targeting exposures similar to the 20 mg once-daily dose for adults. Methods This was a multinational, single-dose, o
Externí odkaz:
https://doaj.org/article/54dcb320922a486c92a064cfcc19124a
Autor:
Stefan Willmann, Kirstin Thelen, Dagmar Kubitza, Anthonie W. A. Lensing, Matthias Frede, Katrin Coboeken, Jan Stampfuss, Rolf Burghaus, Wolfgang Mück, Jörg Lippert
Publikováno v:
Thrombosis Journal, Vol 16, Iss 1, Pp 1-12 (2018)
Abstract Background The EINSTEIN-Jr program will evaluate rivaroxaban for the treatment of venous thromboembolism (VTE) in children, targeting exposures similar to the 20 mg once-daily dose for adults. A physiologically based pharmacokinetic (PBPK) m
Externí odkaz:
https://doaj.org/article/cd6a4e691d8a432894fe4658e16270e0